Pharmacokinetics of bevacizumab and its effects on serum VEGF and IGF-1 in infants with retinopathy of prematurity.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Investigative Ophthalmology and Visual Science

• Publication date

  2015-01-22

• Fields of study

  Medicine

• Identifiers
  DOI 10.1167/iovs.14-15842PMID 25613938
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD

  2014cited by this paper
• Plasma levels of vascular endothelial growth factor before and after intravitreal injection of bevacizumab, ranibizumab and pegaptanib in patients with age-related macular degeneration, and in patients with diabetic macular oedema

  2013cited by this paper
• Vascular endothelial growth factor plasma levels before and after treatment of neovascular age‐related macular degeneration with bevacizumab or ranibizumab

  2012cited by this paper
• Serum concentrations of bevacizumab (avastin) and vascular endothelial growth factor in infants with retinopathy of prematurity.

  2012cited by this paper
• Changes of serum VEGF concentration after intravitreal injection of Avastin in treatment of diabetic retinopathy

  2012cited by this paper
• An update on progress and the changing epidemiology of causes of childhood blindness worldwide.

  2012cited by this paper
• Combine intravitreal bevacizumab injection with laser treatment for aggressive posterior retinopathy of prematurity (AP-ROP).

  2011cited by this paper
• Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity.

  2011cited by this paper
• VEGF Signaling through Neuropilin 1 Guides Commissural Axon Crossing at the Optic Chiasm

  2011cited by this paper
• Bevacizumab for retinopathy of prematurity.

  2011cited by this paper
• Bevacizumab for retinopathy of prematurity.

  2011cited by this paper
• VEGF signalling controls GnRH neuron survival via NRP1 independently of KDR and blood vessels

  2011cited by this paper
• Therapeutic antibodies in ophthalmology

  2010cited by this paper
• Postnatal weight gain modifies severity and functional outcome of oxygen-induced proliferative retinopathy.

  2010cited by this paper
• Ophthalmic drug delivery systems for the treatment of retinal diseases: basic research to clinical applications.

  2010cited by this paper
• FcRn receptor-mediated pharmacokinetics of therapeutic IgG in the eye

  2009cited by this paper
• Immunohistochemical localisation of intravitreally injected bevacizumab in the anterior chamber angle, iris and ciliary body of the primate eye

  2008cited by this paper
• Efficacy of intravitreal injection of bevacizumab for severe retinopathy of prematurity: a pilot study

  2008cited by this paper
• Intravitreous bevacizumab as anti-vascular endothelial growth factor therapy for retinopathy of prematurity: a morphologic study.

  2008cited by this paper
• Monoclonal Antibody Pharmacokinetics and Pharmacodynamics

  2008cited by this paper
• Mapping of the neonatal Fc receptor in the rodent eye.

  2008cited by this paper
• Combination of laser photocoagulation and intravitreal bevacizumab (Avastin®) for aggressive zone I retinopathy of prematurity

  2007cited by this paper
• [IGF-I, VEGF and bFGF as predictive factors for the onset of retinopathy of prematurity (ROP)].

  2006cited by this paper
• Activation of β2-adrenergic receptor stimulates γ-secretase activity and accelerates amyloid plaque formation

  2006cited by this paper
• IGF-I, VEGF Y bFGF, COMO FACTORES PRONÓSTICOS DE LA APARICIÓN DE LA RETINOPATÍA DE LA PREMATURIDAD IGF-I, VEGF AND bFGF AS PREDICTIVE FACTORS FOR THE ONSET OF RETINOPATHY OF PREMATURITY (ROP)

  2006cited by this paper
• The price of sight--ranibizumab, bevacizumab, and the treatment of macular degeneration.

  2006cited by this paper
• Pharmacokinetics and concentration–effect relationships of therapeutic monoclonal antibodies and fusion proteins

  2005cited by this paper
• Final results of the Early Treatment for Retinopathy of Prematurity (ETROP) randomized trial.

  2004cited by this paper
• Insulin-like Growth Factor 1 Induces Hypoxia-inducible Factor 1-mediated Vascular Endothelial Growth Factor Expression, Which is Dependent on MAP Kinase and Phosphatidylinositol 3-Kinase Signaling in Colon Cancer Cells*

  2002cited by this paper
• Low IGF-I suppresses VEGF-survival signaling in retinal endothelial cells: Direct correlation with clinical retinopathy of prematurity

  2001cited by this paper
• Comparisons of the Intraocular Tissue Distribution, Pharmacokinetics, and Safety of 125I-Labeled Full-Length and Fab Antibodies in Rhesus Monkeys Following Intravitreal Administration

  1999cited by this paper
• Regulation of vascular endothelial growth factor-dependent retinal neovascularization by insulin-like growth factor-1 receptor

  1999cited by this paper
• Hypoxic regulation of vascular endothelial growth factor in retinal cells.

  1995cited by this paper
• Permeability of ocular vessels and transport across the blood-retinal-barrier

  1990cited by this paper
• Growth patterns of low birth weight preterm infants: a longitudinal analysis of a large, varied sample.

  1990cited by this paper

• Conformational Dynamics of PKM2 Regulate Hypoxia-Induced Pathological Retinal Angiogenesis

  2025cites this paper
• Study on the Protective Effects and Mechanisms of Atorvastatin in Retinal Ischemia-Reperfusion Injury in Mice.

  2025cites this paper
• Long-Term Assessment of Choroidal Thickness and Refractive Outcomes in Patients Treated for Retinopathy of Prematurity: A Case Control Study.

  2025cites this paper
• Impact of anti‐VEGF therapy versus laser therapy on mortality and treatment outcomes in retinopathy of prematurity: A systematic review and meta‐analysis

  2025influential citation
• Whole Exome Sequencing in Incontinentia Pigmenti: A ROP Mimicker and the Genetic Detection Dilemma.

  2025cites this paper
• Comparing safety and efficacy of Bevacizumab, Ranibizumab and Ranibizumab biosimilar in Retinopathy of prematurity

  2025cites this paper
• Outcomes and comparative analysis of therapeutic approaches for choroidal neovascular membranes associated with optic nerve head drusen in pediatric patients.

  2025cites this paper
• Circulating VEGF-A Levels in Relation to Retinopathy of Prematurity and Treatment Effects: A Systematic Review and Meta-Analysis

  2024cites this paper
• Long-term outcomes of visual motor integration and motor development children with retinopathy of prematurity

  2024cites this paper
• Experiencia con el uso de bevacizumab intravítreo en el manejo de la retinopatía del prematuro tipo I en un país latinoamericano

  2024cites this paper
• Term infant brain MRI after ROP treatment by anti-VEGF injection versus laser therapy.

  2024cites this paper
• Ophthalmic Use of Targeted Biologics in the Management of Intraocular Diseases: Current and Emerging Therapies

  2024cites this paper
• Beyond the Local Effect: An Examination of Cardiovascular and Other Systemic Complications of Ophthalmologic Drugs.

  2024cites this paper
• Bevacizumab for Retinopathy of Prematurity is Not Associated With Systemic Hypertension.

  2024cites this paper
• Experience with the use of intravitreal bevacizumab in cases with type I retinopathy of prematurity in a Latin American country.

  2024cites this paper
• Comparison of Bevacizumab and Aflibercept for Suppression of Angiogenesis in Human Retinal Microvascular Endothelial Cells

  2023cites this paper
• Pathophysiology of Retinopathy of Prematurity.

  2023cites this paper
• An Update on Anti-Vascular Endothelial Growth Factor Treatment for Retinopathy of Prematurity

  2023influential citation
• Intravitreal ranibizumab for retinopathy of prematurity: The ocular and systemic safety profile query

  2023cites this paper
• Efficacy comparison of anti-vascular endothelial growth factor drugs for the treatment of type 1 retinopathy of prematurity: A network meta-analysis of randomised controlled trials

  2023cites this paper
• The Long-Term Observation of the Beneficial Effects of Treatment: 0.12 mg Anti-VEGF Monotherapy or Anti-VEGF Combined Therapy and Diode-Laser in Various Stages of Retinopathy of Prematurity—Series of Cases

  2023cites this paper
• Ranibizumab for the treatment of retinopathy of prematurity: systematic review and meta-analysis

  2023cites this paper
• Efficacy and Safety of Low Dose Intravitreal Ranibizumab for Treatment of Retinopathy of Prematurity

  2023cites this paper
• Respiratory outcomes in preterm infants following intravitreal bevacizumab for retinopathy of prematurity–a 10-year matched case study

  2023cites this paper
• SIRT2 inhibition attenuates the vasculopathy and vision impairment via Akt signaling in retinopathy of prematurity.

  2023cites this paper
• Laser versus Anti-VEGF: A Paradigm Shift for Treatment-Warranted Retinopathy of Prematurity

  2023cites this paper
• Research Progress on Anti-VEGF Drug Ther-apy for Retinopathy of Prematurity

  2023cites this paper
• Retinopathy of prematurity and neurodevelopmental outcomes in preterm infants: A systematic review and meta-analysis

  2023cites this paper
• Eyesight to the Blind-Pharmacotherapy for Retinopathy of Prematurity.

  2023cites this paper
• Reactivation of retinopathy of prematurity after intravitreal bevacizumab monotherapy in aggressive posterior retinopathy of prematurity

  2023cites this paper
• Changes in Serum Concentrations of Vascular Endothelial Growth Factors-A and B after Intravitreal Injection of Ranibizumab and Conbercept for Retinopathy of Prematurity

  2023cites this paper
• Primary and additional treatment preference in aggressive retinopathy of prematurity and type 1 retinopathy of prematurity

  2023cites this paper
• Short-term effects of intravitreal anti-vascular endothelial growth factor agents on body weight and multiple systems after treatment for retinopathy of prematurity

  2023cites this paper
• Evaluation of babies with retinopathy of prematurity following intravitreal bevacizumab administration

  2023cites this paper
• Retinopathy of prematurity: Metabolic risk factors

  2022cites this paper
• Anti-vascular endothelial growth factor therapy in retinopathy of prematurity: An updated literature review

  2022cites this paper
• Structural and refractive outcomes of intravitreal ranibizumab followed by laser photocoagulation for type 1 retinopathy of prematurity

  2022cites this paper
• Comparison of adverse events between intravitreal anti-VEGF and laser photocoagulation for treatment-requiring retinopathy of prematurity: a systematic review

  2022cites this paper
• Pulmonary Hypertension in Preterm Infants Treated With Laser vs Anti-Vascular Endothelial Growth Factor Therapy for Retinopathy of Prematurity.

  2022cites this paper
• Postnatal Growth Trajectories and Neurodevelopmental Outcomes Following Bevacizumab Treatment for Retinopathy of Prematurity

  2022cites this paper
• Retinopathy of Prematurity: A Global Perspective and Recent Developments.

  2022cites this paper
• A Network Meta-Analysis of Retreatment Rates following Bevacizumab, Ranibizumab, Aflibercept and Laser for Retinopathy of Prematurity.

  2022cites this paper
• Intravitreal Bevacizumab is Associated with Prolonged Ventilatory Support in Preterm Infants with Bronchopulmonary Dysplasia.

  2022cites this paper
• Low- and Very Low-Dose Bevacizumab for Retinopathy of Prematurity: Reactivations, Additional Treatments, and 12-Month Outcomes.

  2022cites this paper
• National guideline for ophthalmological screening of premature infants in Germany (S2k level, AWMF guidelines register no. 024/010, March 2020)

  2022cites this paper
• The Role of Insulin-like Growth Factor-1 and Its Receptor in the Eye: A Review and Implications for IGF-1R Inhibition

  2022cites this paper
• Analysis of optical coherence tomography angiographic findings of prematurely born children and its relationship with macular edema of prematurity.

  2022cites this paper
• Plasma Levels of Bevacizumab and Vascular Endothelial Growth Factor After Low-Dose Bevacizumab Treatment for Retinopathy of Prematurity in Infants.

  2022cites this paper
• Aggressive Posterior Retinopathy of Prematurity: Long-Term Outcomes Following Intravitreal Bevacizumab

  2022cites this paper
• Serum vascular endothelial growth factor, insulin-like growth factor-1 and aflibercept levels in retinopathy of prematurity

  2022cites this paper
• The role of anti-vascular endothelial growth factor in treatment of retinopathy of prematurity—a current review

  2022influential citation
• Eligibility Criteria and Representativeness of Randomized Clinical Trials That Include Extremely Premature Infants: A Systematic Review.

  2021cites this paper
• Hypertension in neonates treated with intravitreal bevacizumab for retinopathy of prematurity

  2021cites this paper
• Bevacizumab and neurodevelopmental outcomes of preterm infants with retinopathy of prematurity: should we still worry?

  2021cites this paper
• Neurodevelopmental Outcomes in Preterm Infants with Retinopathy of Prematurity.

  2021cites this paper
• Augenärztliche Screening-Untersuchung bei Frühgeborenen (S2k-Level, AWMF-Leitlinien-Register-Nr. 024/010, März 2020)

  2021cites this paper
• Effect of intravitreal bevacizumab for retinopathy of prematurity on weight gain

  2021cites this paper
• Survey of current retinopathy of prematurity practices in China.

  2021cites this paper
• 2-year outcomes of ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW extension study): prospective follow-up of an open label, randomised controlled trial.

  2021cites this paper
• Combined intravitreal ranibizumab and zone I sparing laser ablation in infants with posterior zone I retinopathy of prematurity

  2021cites this paper
• Systemic exposure following intravitreal administration of therapeutic agents: an integrated pharmacokinetic approach. 1. THR-149

  2021cites this paper
• Complications of retinopathy of prematurity treatment

  2021cites this paper
• Neurodevelopmental Outcomes Following Anti-VEGF Treatment for ROP

  2021cites this paper
• Conserved regression patterns of retinopathy of prematurity after intravitreal ranibizumab: A class effect

  2020cites this paper
• Stanniocalcin-1 is a Modifier of Oxygen-Induced Retinopathy Severity

  2020cites this paper
• Contralateral effect of systemic absorption of low dose bevacizumab (Avastin) after unilateral intravitreal injection in severe retinopathy of prematurity (ROP)

  2020cites this paper
• Strategies to Prevent Severe Retinopathy of Prematurity: A 2020 Update and Meta-analysis.

  2020cites this paper
• Inhibition of retinal neovascularization by a PEDF-derived nonapeptide in newborn mice subjected to oxygen-induced ischemic retinopathy.

  2020cites this paper
• Treatment of retinopathy of prematurity (ROP) outside International Classification of ROP (ICROP) guidelines

  2020cites this paper
• Short-term Outcomes After Very Low-Dose Intravitreous Bevacizumab for Retinopathy of Prematurity.

  2020cites this paper
• The Short-Term Effects of Intravitreal Injection of Bevacizumab on the Plasma Levels of Vascular Endothelial Growth Factor, Insulin-Like Growth Factor-1, and Growth Parameters in Infants with Retinopathy of Prematurity

  2020cites this paper
• Update on Anti-Vascular Endothelial Growth Factor Safety for Retinopathy of Prematurity.

  2020cites this paper
• Stellungnahme der Deutschen Ophthalmologischen Gesellschaft, der Retinologischen Gesellschaft und des Berufsverbands der Augenärzte Deutschlands zur Anti-VEGF-Therapie der Frühgeborenenretinopathie

  2020cites this paper
• Ranibizumab Population Pharmacokinetics and Free VEGF Pharmacodynamics in Preterm Infants With Retinopathy of Prematurity in the RAINBOW Trial

  2020cites this paper
• Bevacizumab in Retinopathy of Prematurity : Concerns and adverse effects.

  2020cites this paper
• Statement of the German Society of Ophthalmology, the German Retina Society, and the Professional Association of German Ophthalmologists on anti-VEGF therapy of retinopathy of prematurity

  2020cites this paper
• Neurodevelopmental Outcomes After Bevacizumab Treatment for Retinopathy of Prematurity-A Meta-Analysis.

  2020cites this paper
• Update on the Use of Anti-VEGF Drugs in the Treatment of Retinopathy of Prematurity.

  2020cites this paper
• Neurodevelopmental outcomes following bevacizumab treatment for retinopathy of prematurity: a systematic review and meta-analysis

  2020cites this paper
• Acute and chronic effects of intravitreal bevacizumab on lung biomarkers of angiogenesis in the rat exposed to neonatal intermittent hypoxia

  2020cites this paper
• Optimizing Measurement of Vascular Endothelial Growth Factor in Small Blood Samples of Premature Infants

  2019cites this paper
• Ocular Biodistribution of 89Zr-Bevacizumab in New Zealand Rabbits Determined Using PET/MRI: A Feasibility Study

  2019cites this paper
• Can IL-33 and Endocan be New Markers for Retinopathy of Prematurity?

  2019cites this paper
• Neurodevelopmental Outcomes after Intravitreal Bevacizumab Therapy for Retinopathy of Prematurity: A Prospective Case-Control Study.

  2019cites this paper
• Neurodevelopmental Outcomes of Preterm Infants With Retinopathy of Prematurity by Treatment

  2019cites this paper
• Plasma VEGF Concentrations after Intravitreous Anti-VEGF Therapy for Diabetic Macular Edema

  2019cites this paper
• EB_A_189684 25..35

  2019cites this paper
• Involution of retinopathy of prematurity and neurodevelopmental outcomes after intravitreal bevacizumab treatment

  2019cites this paper
• Prematür retinopatisinin tanısı ve lazer tedavisine cevabın takibinde VEGF ve IGF-1’in değeri

  2019cites this paper
• Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): an open-label randomised controlled trial.

  2019cites this paper
• Evidence to date: ranibizumab and its potential in the treatment of retinopathy of prematurity

  2019cites this paper
• Screening and novel therapies for retinopathy of prematurity - A review.

  2019cites this paper
• The value of VEGF and IGF-1 in the diagnosis retinopathy of prematurity and follow-up of response to laser therapy

  2019cites this paper
• Neurodevelopmental Outcomes of Preterm Infants With Retinopathy of Prematurity by Treatment

  2019cites this paper
• RATES AND RISK FACTORS FOR RECURRENCE OF RETINOPATHY OF PREMATURITY AFTER LASER OR INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR MONOTHERAPY.

  2019cites this paper
• A Dosing Study of Bevacizumab for ROP: Late Recurrences and Additional Treatments

  2019cites this paper
• Anti-vascular endothelial growth factor intravitreal therapy for retinopathy of prematurity.

  2019cites this paper
• Refractive Outcomes of 4-Year-old Children after Intravitreal Anti-vascular Endothelial Growth Factor versus Laser Photocoagulation for Retinopathy of Prematurity

  2019cites this paper
• Overexpression of Annexin A2 Receptor Inhibits Neovascularization via the Promotion of Krüppel-Like Transcription Factor 2

  2018cites this paper
• Anti-vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity.

  2018cites this paper